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Introduction: Colorectal Cancer (CRC) is the third most common cancer and the second lead-
ing  cause of death in Western countries. In Portugal, in the North, emerges as the second
most common cancer. The presence of lymph node metastasis is an important predictor
of  overall and disease-free survival and several studies recommend the evaluation of at
least  12–14 regional lymph nodes, as it contributes to improve cancer staging and patient
outcomes.
Aims: Epidemiological characterization of the studied population and identify a possible
relationship between the number of lymph nodes evaluated in the surgical specimen and
survival.
Methods: We  preceded to the study of 1065 CCR patients, submitted to surgical resection
between 1 January 2000 and 31 August 2012, in Braga Hospital.
Discussion/Conclusion: The results of the epidemiological characterization of this population
are  coincident with those described in the literature. It was observed a signiﬁcant correla-
tion  between age, tumor size, serosal invasion, differentiation, tumor penetration, venous
and lymphatic invasion, metastasis, TNM stage and the number of lymph nodes evaluated.
However, we did not observe a statistically signiﬁcant correlation between patient survival
and number of lymph nodes evaluated (p > 0.05). A possible explanation is the practice of
oncologists, addressing patients with less than 12 nodes identiﬁed in the surgical speci-
men  as “N-positive” and undergoing adjuvant therapy. A better harvest and careful analysis
of  lymph nodes would lead to more accurate staging, avoiding overtreatment and side
effects associated, and allow better economic management of hospital resources, in real
N0  patients.© 2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de
Coloproctologia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2237-9363/© 2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Coloproctologia. This is an open access article
under  the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Impacto  prognóstico  do  número  de  linfonodos  ressectados  na  sobrevida
de  pacientes  com  câncer  colorretal
Palavras-chave:
Câncer colorretal
Linfonodos
Estadiamento
Sobrevida
r  e  s  u  m  o
Introduc¸ão: O câncer colorretal (CCR) ocupa o terceiro lugar em termos de frequência e, além
disso, é a segunda causa principal de morte nos países ocidentais. Em Portugal, no norte,
CCR  surge como o segundo câncer mais comum. A presenc¸a de metástase aos linfonodos
é  preditor importante de sobrevida em geral e de sobrevida livre da doenc¸a; vários estudos
recomendam a avaliac¸ão de pelo menos 12–14 linfonodos regionais, pois tal procedimento
contribui para aprimorar o estadiamento do câncer e os desfechos para os pacientes.
Objetivos: Caracterizac¸ão epidemiológica da populac¸ão estudada e identiﬁcac¸ão de possível
relac¸ão  entre o número de linfonodos avaliados no espécime cirúrgico e sobrevida.
Métodos: Estudo de 1065 pacientes com CCR, submetidos à ressecc¸ão cirúrgica entre 1 de
janeiro de 2000 e 31 de agosto de 2012 em um hospital em Braga.
Discussão/Conclusão: Os resultados da caracterizac¸ão epidemiológica dessa populac¸ão coin-
cidem com os resultados descritos na literatura. Foi observada uma  correlac¸ão signiﬁcativa
entre idade, tamanho do tumor, invasão da serosa, diferenciac¸ão, penetrac¸ão tumoral,
invasão venosa e linfática, metástase, estágio TNM e número de linfonodos avaliados. Mas
não  observamos uma correlac¸ão estatisticamente signiﬁcativa entre sobrevida do paciente e
número de linfonodos avaliados (p > 0,05). Uma explicac¸ão possível é a prática dos oncologis-
tas,  que tratam pacientes com menos de 12 nodos identiﬁcados no espécime cirúrgico como
“N-positivos”, prosseguindo com terapia adjuvante. Uma coleta mais apropriada e uma
análise cuidadosa dos linfonodos resultaria em um estadiamento mais preciso, evitando
o  tratamento excessivo e os efeitos colaterais associados, além de permitir um tratamento
com melhor custo-benefício para os recursos hospitalares em pacientes realmente N0.
©  2016 Publicado por Elsevier Editora Ltda. em nome de Sociedade Brasileira de
Coloproctologia. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://
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Introduction
he Colorectal Cancer (CRC) is the third most common cancer
nd the second leading cause of death in the United States and
n Western countries.1 In the north of Portugal, it arises as the
econd most common cancer, with an incidence rate of 41.6%,
nd 34% in the district of Braga.2 Data from the World Health
rganization between 1997 and 2007 revealed that the mortal-
ty rate declined about 2% per year: 19.7 to 17.4/100 000 for
en  (world standardized rates), and from 12.5 to 10.5/100 000
or women and this decrease is due to early diagnosis and
reatment, with a consequent increase in survival.3
The stage of the CRC at diagnosis is the primary determi-
ant of survival and the main predictor of mortality.4 The
urvival rates at ﬁve years may be higher than 90% if the
iagnosis is made at an early stage, however only 37% of
he cases are diagnosed at this stage.5 Lymph node metas-
ases are an important factor for the indication of adjuvant
hemotherapy and perform an important predictor of overall
nd disease-free survival. There is evidence of improved onco-
ogical outcomes and cancer staging as greater the number
f lymph nodes identiﬁed.6,7 However, the number of lymph
odes that should be evaluated remains controversial.8 The
nternational Union against Cancer,  the American Joint Commit-
ee on Cancer,  the American College of Surgeons and the National
uality Forum consider that is necessary to review at least
welve lymph nodes to exclude the achievement of disease.9,10
n the 7th edition of the AJCC Cancer Staging Manual, it iscreativecommons.org/licenses/by-nc-nd/4.0/).
recommended to evaluate at least twelve to fourteen regional
lymph nodes as a prognostic factor of CRC, and evaluation
of fewer than twelve lymph nodes have low discriminative
power.11 Statistical analysis showed that probability of ﬁnd-
ing a single metastasis in lymph nodes increases with the
number of nodes and decreases about 46% when only eigh-
teen nodes are found.12 Thus, it is recommended that small
ganglia between 0.1 and 0.2 cm in diameter must be located.
Nevertheless, further investigations revealed that over 60% of
U.S. institutions fail in achieving the proposed target of a min-
imum of twelve lymph nodes assessed.13 Some researchers
believe that radical lymphadenectomy has a beneﬁcial ther-
apeutic effect while others believe that this only provides a
more  accurate staging.14
Factors  contributing  to  the  number  of  nodes  evaluated
It has been shown that the relation between the number
of nodes evaluated and staging is not simple. Three major
factors inﬂuencing this relation were identiﬁed: the hospital
(quality of oncological and surgical care and number of can-
cer cases), the patient characteristics (younger age ≤ 60 years,
female sex), and tumor properties (larger size and greater
tumor extension (pT), right colon localization, and higher
stage). These factors are associated with higher lymph nodes
achievement. Thus, a low number of nodes examined can be
an indicator of poor surgical and oncological care.6,15 Among
the factors contributing to the number of nodes evaluated
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in resected specimens, the methodology used in pathologi-
cal practice is the most important (namely in collection of
lymph nodes and processing for microscopic examination).
The non-uniformity of this approach is currently the most
problematic factor,15 making the role of the pathologist essen-
tial given that an extensive pathologic diagnosis will allow a
correct staging.16
Other factors contributing to the variation in the number
of nodes contained in the surgical specimen are the surgical
technique and the variations in the specimens manipulation:
diligence of search for lymph nodes, the use of solutions to
increase macroscopic visualization of nodes; threshold for
acceptable number of lymph nodes using half versus all lymph
nodes found for microscopic evaluation; amount of tissue
acquired for observation, and the separation of nodes by
anatomic site. Thus, it is recommended that all lymph nodes
found should be sectioned, and it has been demonstrated
that twelve to ﬁfteen negative nodes are predictors of nega-
tive regional lymph node invasion. If less than twelve nodes
are found, then additional techniques to improve visualization
should be considered.15
Another factor in rectal cancer that inﬂuences the num-
ber of nodes evaluated is neoadjuvant therapy,17,18 including
preoperative radiation therapy.19 According to some authors,
this therapy improves resectability, sphincter preservation
and local control of the disease, although its survival ben-
eﬁt is controversial since the reduction of recurrence does
not necessarily translate into increased survival rate.17,20–22 In
addition, the neoadjuvant therapy is associated with reduc-
tion in tumor mass, but also with increased tissue ﬁbrosis,
which hampers identiﬁcation of the lymph nodes.23 The
hypothesis that fewer lymph nodes are detected in the sur-
gical specimen after neoadjuvant therapy has been conﬁrmed
by several authors.24–26 There are currently no recommenda-
tions on the actual number of lymph nodes that should be
found after neoadjuvant therapy (staging ypN), however in
the literature the mean nodes found varies between four and
fourteen.27,28
Neoadjuvant therapy also appears to have an important
effect on mesorectal lymph nodes, contributing to decrease in
their size.29–31 Murphy et al.32 have identiﬁed the size of lymph
nodes as an independent prognostic indicator of survival in
negative nodes after primary surgery. It is believed that a sig-
niﬁcant number of mesorectal lymph nodes micrometastases,
smaller than 0.5 cm are not detected by manual lymph nodes
counting and by typical pathological diagnosis methods.17
Some authors concluded that the absence of nodes (ypNx)
or decreased number of nodes found in patients with stage
ypN-negative does not imply a poorer oncologic outcome. The
number of nodes seems to have no impact on survival and
recurrence in patients’ ypN-negative.33 If fewer than twelve
lymph nodes are found and there is no opportunity to ﬁnd
more,  adjuvant therapy is recommended in high risk situa-
tions. The failure to reach a minimum mark of twelve nodes
found is currently used by oncologists in their treatment
decisions.17Given the controversial theme and the absence of studies
in Portugal, this study was conducted in order to character-
ize epidemiologically patients operated by CRC in the period
January 1, 2000 to August 31, 2012, at Braga Hospital and 1 6;3  6(3):130–138
identiﬁes a possible relation between the number of lymph
nodes examined and the survival of patients operated for CRC.
Materials  and  methods
Data from 1065 patients treated in Braga Hospital, north of Por-
tugal, between January 1, 2000, and August 31, 2012 with CRC
diagnosis and submitted to surgical treatment was collected
retrospectively.
Data collected from clinical and preoperative diagnos-
tic examinations includes: age, gender and tumor location.
Histopathological reports include: tumor size, serosal exten-
sion, presence of sincrone tumors, histological type, tumor
differentiation, macroscopic tumor appearance, tumor extent
(T), number of lymph nodes evaluated and extent of spread
to the lymph nodes (N), lymphatic and blood vessel inva-
sion, and TMN  staging. The level of positive lymph nodes was
not described in all specimens. Two experienced pathologists
determined the histological type of CRC and the tumor staging
was graded according to TNM classiﬁcation, 6th edition.
All patients were followed up periodically and their out-
comes were investigated and collected until August 2012.
Follow-up data recorded included recurrence of the disease
and time of death.
Statistical  analysis
All data was collected and stored in an Excel PC database
and statistically analyzed using the Statistical Package for the
Social Sciences, version 22.0 (SPSS Inc., Chicago, Illinois, USA).
A simple descriptive analysis of each one of the variables was
realized, with determination of the total number of cases and
relative frequencies. The median and mean was determined
for the number of lymph nodes assessed.
All comparisons were examined for statistical signiﬁcance
using Pearson’s chi-square (2) test and Fisher’s exact test
(when n < 5), with the threshold for signiﬁcance p values < 0.05.
Overall survival (OS) was deﬁned as time from disease diag-
nosis until death from any cause, and it was assessed using
the Kaplan–Meier method.
Ethics  committee  approval
The study protocol was approved by the Ethics Committee of
Braga Hospital.
Results
1384 patients were identiﬁed with the diagnosis of CRC, and
1065 of these met  the inclusion criteria previously deﬁned.
Epidemiological characterization of the patients is pre-
sented in Table 1, as well as the median and the mean lymph
nodes retrieved for each variable analyzed. The median (Md) of
lymph nodes retrieved, in this population, was eleven and the
mean was thirteen nodes. The frequency of CRC was higher
in men  (59.8%, n = 637) than in women (40.2%, n = 428), reach-
ing more  patients aged less than 71.5 years (53.8%, n = 573).
The median lymph nodes retrieved was equal in both sexes,
eleven lymph nodes.
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Table 1 – Epidemiological characterization of patients and its relationship with the mean and median number of lymph
nodes evaluated.
Variable n % Median number of
nodes retrieved
Mean  number of
nodes retrieved
Overall 1065 100 11 13
Sex
Female 428 40.2 11 13
Male 637 59.8 11 13
Age (years)
≤71.5 573 53.8 11  14
>71.5 492 46.2 10 12
Location
Right colon 243 22.8 13 15
Left colon 486 45.6 10 12
Rectum 336 31.5 10 13
Tumor size (cm)
≤4.5 597 56.1 9 12
>4.5 419 39.3 13 15
Serous invasion
Absent 257 24.1 8 12
Present 791 74.3 11 13
Sincrone tumors
No 1034 97.1 11 13
Yes 30 2.8 11 16
Histological type
Adenocarcinoma 898 84.3 10 13
Mucinous adenocarcinoma 121 11.4 13 15
Invasive adenocarcinoma 36 3.4 9 10
Signet ring & mucinous cells 10 0.9 12 31
Histological grade
Differentiated 438 41.1 10 11
Undifferentiated 53 5.0 11  12
Depth of invasion
Tis 13 1.2 7 19
T1 50 4.7 7 9
T2 148 13.9 9 12
T3 758 71.2 11 13
T4 63 5.9 11 16
Nodes retrieved
<12 583 54.7 - -
≥12 457 42.9 - -
Invaded nodes
0 606 56.9 - -
01/mar 289 27.1 - -
≥4 145 13.6 - -
pN
pN0 596 56.0 10 13
pN1 293 27.5 10 11
pN2 149 14.0 13 15
pM
pM0 820 77.0 11 13
pM1 125 11.7 11 15
Resection margins
Without involvement 1007 94.6 11 13
Involved 36 3.4 11 15
Venous Invasion
Without 595 55.9 10 13
With 407 38.2 11 13
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Table 1 – (Continued)
Variable n % Median number of
nodes retrieved
Mean  number of
nodes retrieved
Lymphatic Invasion
Without 383 36.0 10 13
With 478 44.9 11 13
Stage
I 168 15.8 8 12
II 392 36.8 10 13
III 369 34.7 11 15
IV 126 11.8 11 15
Relapse
Absent 790 74.2 11 14
Present 151 14.2 11 11
Differentiated, well and moderately differentiated tumors; Undifferentiated, poorly differentiated and undifferentiated tumors; Tis, intra-
mucous/in situ carcinoma;  T1, submucous invasion; T2, muscularis propria invasion; T3, subserosous/not peritonized pericolic conjunctive tissue
invasion; T4, organs and structures invasion.More  nodes were found in patients aged less than 71.5 years
(median 11 nodes). Regarding its location, the tumors were
more  often in the colon (68.4%, n = 729), particularly in the left
colon (45.6%, n = 486). The median lymph nodes evaluated was
greater in the right colon (Md  = 13), followed by the left colon
and rectum, both with the same median (Md  = 10). In 56.1%
(n = 597) of cases, the tumor showed a dimension ≤ 4.5 cm,  with
more  serosal invasion (74.3%, n = 791). The majority of patients
had no synchronous tumors (97.1%, n = 1034). The median of
nodes was greater in tumors > 4.5 cm (Md  = 13), and in tumors
with serosal invasion (Md  = 11). The presence of synchronous
tumors had no impact in the median of nodes assessed (eleven
nodes in both cases).
Histologically, the tumors were mainly adenocarcinoma
(84.3%, n = 898), and mucinous adenocarcinoma was the sec-
ond most frequent tumor (11.4%, n = 121), followed by invasive
adenocarcinoma in 3.4% of cases (n = 36). Tumors with signet
ring cells and mucinous areas had a small frequency (0.9%,
n = 10). The median nodes retrieved was greater in mucinous
adenocarcinoma (Md  = 13), followed by tumors with signet
ring cells and mucinous areas (Md  = 12) and adenocarcinoma
(Md  = 10). Invasive adenocarcinoma had the lower median
nodes evaluated (Md  = 9).
Relatively to tumor extension (T), the majority of tumors
are classiﬁed as T3 (71.2%, n = 758), followed by T2 in 13.9% of
cases (n = 148). T4 lesions were present only in 5.9% of cases
(n = 63), followed by the T1 (4.7%, n = 50) and Tis in 1.2% of cases
(n = 13). The higher median nodes was found in T3 and T4
tumors (Md  = 11).
Differentiated tumors were more  frequent (41.1%, n = 438)
than undifferentiated (5%, n = 53). However, undifferentiated
tumors had higher median nodes (Md  = 11). Regarding the
number of lymph nodes in surgical specimen, 54.7% (n = 583)
of patients had less than twelve nodes retrieved, whereas in
42.9% (n = 457), twelve or more  lymph nodes were assessed.
In the great majority, 56.9% of cases (n = 606), no metastatic
lymph node was found, and in 27.1% (n = 289) of patients 1–3
metastatic lymph nodes were found. In only 13.6% (n = 145)cases, four or more  lymph nodes were invaded. In 94.6% of
cases (n = 1007), there was free surgical margins with no neo-
plastic lesion, and in 3.4% of cases (n = 36) the tumor was
intercepted by margins of excision, and median ganglia found
in both cases was the same (Md = 11).
More patients had no venous involvement (55.9%, n = 595)
but most had lymphatic invasion (44.9%, n = 478). The median
of nodes assessed was greater in the presence of venous and
lymphatic involvement (Md = 11). Most patients (56%, n = 596)
were classiﬁed as N0, followed by N1 in 27.5% (n = 293) and
N2 in 13.9% of patients (n = 148). In 77% of cases (n = 820)
there was no distant metastases. pN2 stage recorded higher
median nodes assessed (Md = 13) and the presence or absence
of distant metastases (PM0 and pM1) had no inﬂuence on this
result (Md = 11). The stages II and III were the most frequently
observed in 36.8% (n = 392) and 34.7% (n = 369) of cases, respec-
tively. The stages III and IV were those who reported higher
median nodes assessed (Md = 11).
74.2% of patients (n = 790) were free of relapses, and the
median lymph nodes evaluated was 11, regardless of the exist-
ence of recurrences. The majority of patients, 59.6% (n = 635),
are alive, and the median nodes assessed was higher in
this patients (Md = 11). Relating the number of nodes ana-
lyzed with several variables (Table 2), signiﬁcant correlations
were found with: age (p = 0.002), tumor size (p = 0.000), serosal
invasion (p = 0.000), differentiation (p = 0.000), tumor pene-
tration (p = 0.000), venous and lymphatic invasion (p = 0.000),
presence of metastasis (p = 0.000) and TNM stage (p = 0.003).
There were no statistically signiﬁcant correlations with gen-
der (p = 0.787), tumor location (p = 0.331); synchronous tumors
(p = 0.921), histological type (p = 0.055), and resection margins
invasion (p = 0.152).
Figs. 1–3 represent survival curves (for all patients, colon
cancer patients and rectal cancer patients, respectively)
related with the number of lymph nodes assessed in surgical
specimen. Although in the early months after surgery survival
is greater in patients with evaluation of twelve or more  nodes,
this result is not statistically signiﬁcant (p > 0.05).
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Table 2 – Relationship between variables and number of lymph nodes examined.
Variable n (%) p
<12 nodes ≥12 nodes
Sex
Female 237 (40.7%) 182 (39.8%) 0.787
Male 346 (59.3%) 275 (60.2%)
Age (years)
≤71.5 288 (49.4%) 270 (59.1%) 0.002
>71.5 295 (50.6%) 187 (40.9%)
Location
Right colon 70 (24.5%) 50 (23.8%) 0.331
Left colon 134 (46.9%) 111 (52.9%)
Rectum 82 (28.7%) 49 (23.3%)
Tumor size (cm)
≤4.5 389 (68.7%) 201 (45.6%) 0.000
>4.5 177 (31.3%) 240 (54.4%)
Serous invasion
Absent 96 (33.6%) 25 (11.9%) 0.000
Present 190 (66.4%) 185 (88.1%)
Sincrones tumors
No 276 (96.5%) 203 (96.7%) 0.921
Yes 10 (3.5%) 7 (3.3%)
Histological type
Adenocarcinoma 245 (85.7%) 170 (81%) 0.055
Mucinous adenocarcinoma 26 (9.1%) 27 (12.9%)
Invasive adenocarcinoma 15 (5.2%) 9 (4.3%)
Signet ring & mucinous cells 0 (0%) 4 (1.9%)
Histological grade
Differentiated 268 (95.7%) 167 (81.1%) 0.000
Undifferentiated 12 (4.3%) 39 (18.9%)
Depth of invasion
Tis 16 (2.8%) 7 (1.6%) 0.000
T1 38 (6.6%) 8 (1.8%)
T2 97 (17%) 50 (11%)
T3 389 (68%) 358 (79%)
T4 32 (5.6%) 30 (6.6%)
Resection margins
Without involvement 280 (98.2%) 200 (96.2%) 0.152
Involved 5 (1.8%) 8 (3.8%)
Venous invasion
Absent 198 (71%) 70 (34.7%) 0.000
Present 81 (29%) 132 (65.3%)
Lymphatic invasion
Absent 187 (67%) 19 (9.9%) 0.000
Present 92 (33%) 172 (90.1%)
Stage
I 112 (19.2%) 54 (11.8%) 0.003
II 220 (37.8%) 170 (37.8%)
III 188 (32.3%) 175 (38.3%)
IV 62 (10.7%) 58 (12.7%)
pM
M0 266 (93%) 160 (76.2%) 0.000
M1 20 (7%) 50 (23.8%)
Differentiated, well and moderately differentiated tumors; Undifferentiated, poorly differentiated and undifferentiated tumors; Tis, intra-
mucous/in situ Ca; T1, submucous invasion; T2, muscularis propria invasion; T3, subserosous/not peritonized pericolic conjunctive tissue
invasion; T4, organs and structures invasion.
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Fig. 1 – Survival curve in function of the number of lymph
node evaluated in CRC patients submitted to surgical
treatment, assessed by log-rank test (p = 0.642).
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Fig. 2 – Survival curve in function of the number of lymph
node evaluated in Colon Cancer patients submitted to
surgical treatment, assessed by log-rank test (p = 0.171).
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Fig. 3 – Survival curve in function of the number of lymph
node evaluated in Rectal Cancer patients submitted to
surgical treatment, assessed by log-rank test (p = 0.204).
Discussion/Conclusion
Pathological staging is a major prognostic factor for CRC and
the regional lymph node metastases are one of the strongest
predictors of outcome after surgical resection. Currently, sev-
eral guidelines suggest a minimum score of 12 lymph nodes
assessed in the surgical specimen as a prognostic factor of
CRC.11,34–36
The results of patient’s epidemiological characterization, in
this study, coincide with those mentioned by several authors,
highlighting this region as an area of high incidence of CRC.
In this study, the distribution of CRC by sex and age is well
proven, affecting more  men  than women and noting a higher
incidence in individuals aged less than 71.5 years. In this pop-
ulation, colon tumors, left colon in particular, were the most
prevalent, and adenocarcinoma was the most common his-
tological type, as documented in the literature.37–39 Data of
countries with high incidence of CRC show that about 20% of
patients are diagnosed in stage IV and 25% in stage I,4,40,41
which coincides with the results obtained.
We  observed a signiﬁcant correlation between the number
of nodes evaluated and the variables: age, tumor size, serosal
invasion, differentiation, penetration, venous and lymphatic
invasion, presence of metastases and TNM stage. This number
is lower in older patients, and a possible explanation may be
that the number of lymph nodes tends to decrease with age.42
Larger tumors, with greater penetration tumor (pT) stage and
with serosal invasion, venous and lymphatic involvement and
presence of metastases are associated with a greater number
of nodes assessed. Since the technique of surgical resection
and lymphadenectomy are standardized, it is unlikely that
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his is due to surgical technique. On the other hand, these fac-
ors relate to poor prognosis and can thus be associated with
ncreased nodes dimension and consequently better visual-
zation and collection by the pathologists and also a greater
iligence in identiﬁcation of associated nodes.
This study also demonstrate that factors such as age,
ocation, tumor size, histologic type, venous and lymphatic
nvasion, and tumor penetration inﬂuence the median nodes
ssessed. This number is higher in tumors ≥ 4.5 cm,  right
olon tumors, patients aged ≤72.5 years, tumors with venous
nd lymphatic invasion, in mucinous adenocarcinoma and in
umors with invasion of subserous or other organs/structures
higher pT), which goes against the literature.15 However, sex,
esection margins involvement, presence of distant metas-
ases and relapses did not have any inﬂuence on the median
odes assessed, unlike reported in various studies.
The results demonstrate that in the case of colon tumors,
ssessment of twelve or more  nodes results in a greater sur-
ival. In rectal cancer, it was found that survival decreases
fter approximately twenty-ﬁve months of diagnosis, com-
ared to patients with less than twelve lymph nodes
valuated. However, these results are not statistically signif-
cant (p > 0.05), and it is not possible to admit the existence
f a correlation between survival and the number of nodes
ssessed be larger or smaller/equal to twelve. The results
btained in this study contradict various studies and cur-
ent recommendations. This is a controversial topic, and the
ptimal number of nodes to evaluate, in order to obtain sig-
iﬁcant results in patients survival, is still highly debated and
uestionable. One possible explanation for the results of this
tudy lies in the fact that is common practice of the onco-
ogists in this hospital label patients with less than twelve
odes, identiﬁed in surgical recession, as “N-positive”; thus,
hese patients are subjected to adjuvant therapy if their gen-
ral condition permits. This means that they are overtreated
atients who might actually be N0, but are treated as having
odal metastases since less than twelve nodes were retrieved.
t is not possible to rule out other factors that also inﬂu-
nce survival, including comorbidities, performed treatments
nd post-surgical mortality. Surgical and pathological tech-
iques should also be taken into consideration in obtaining
ymph nodes.15,16 A more  careful resection of mesorectum
nd a more  accurate nodes pathological evaluation contribute
o improved staging and therefore more  accurate evaluation
nd patient follow up. Thus, subject patients for adjuvant
reatment toxicity, for which this is unnecessary, could be
voided, reducing consequent hospital costs, both economic
nd humans.
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